These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33846387)

  • 1. Dyskinesia estimation during activities of daily living using wearable motion sensors and deep recurrent networks.
    Hssayeni MD; Jimenez-Shahed J; Burack MA; Ghoraani B
    Sci Rep; 2021 Apr; 11(1):7865. PubMed ID: 33846387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dyskinesia Severity Estimation in Patients with Parkinson's Disease Using Wearable Sensors and A Deep LSTM Network.
    Hssayeni MD; Jimenez-Shahed J; Burack MA; Ghoraani B
    Annu Int Conf IEEE Eng Med Biol Soc; 2020 Jul; 2020():6001-6004. PubMed ID: 33019339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Objective motion sensor assessment highly correlated with scores of global levodopa-induced dyskinesia in Parkinson's disease.
    Mera TO; Burack MA; Giuffrida JP
    J Parkinsons Dis; 2013 Jan; 3(3):399-407. PubMed ID: 23948993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative assessment of levodopa-induced dyskinesia using automated motion sensing technology.
    Mera TO; Burack MA; Giuffrida JP
    Annu Int Conf IEEE Eng Med Biol Soc; 2012; 2012():154-7. PubMed ID: 23365855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early morning off-medication dyskinesias, dystonia, and choreic subtypes.
    Cubo E; Gracies JM; Benabou R; Olanow CW; Raman R; Leurgans S; Goetz CG
    Arch Neurol; 2001 Sep; 58(9):1379-82. PubMed ID: 11559308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Motion sensor dyskinesia assessment during activities of daily living.
    Pulliam CL; Burack MA; Heldman DA; Giuffrida JP; Mera TO
    J Parkinsons Dis; 2014; 4(4):609-15. PubMed ID: 25208729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multiple motion sensors index for motor state quantification in Parkinson's disease.
    Aghanavesi S; Westin J; Bergquist F; Nyholm D; Askmark H; Aquilonius SM; Constantinescu R; Medvedev A; Spira J; Ohlsson F; Thomas I; Ericsson A; Buvarp DJ; Memedi M
    Comput Methods Programs Biomed; 2020 Jun; 189():105309. PubMed ID: 31982667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel method for assessing the severity of levodopa-induced dyskinesia using wearable sensors.
    Lee SI; Daneault JF; Golabchi FN; Patel S; Paganoni S; Shih L; Bonato P
    Annu Int Conf IEEE Eng Med Biol Soc; 2015 Aug; 2015():8087-90. PubMed ID: 26738170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation.
    Li MH; Mestre TA; Fox SH; Taati B
    J Neuroeng Rehabil; 2018 Nov; 15(1):97. PubMed ID: 30400914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials.
    Pahwa R; Isaacson S; Jimenez-Shaheed J; Malaty IA; Deik A; Johnson R; Patni R
    Parkinsonism Relat Disord; 2019 Mar; 60():118-125. PubMed ID: 30292734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous Assessment of Levodopa Response in Parkinson's Disease Using Wearable Motion Sensors.
    Pulliam CL; Heldman DA; Brokaw EB; Mera TO; Mari ZK; Burack MA
    IEEE Trans Biomed Eng; 2018 Jan; 65(1):159-164. PubMed ID: 28459677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease.
    Herring WJ; Assaid C; Budd K; Vargo R; Mazenko RS; Lines C; Ellenbogen A; Verhagen Metman L
    Clin Neuropharmacol; 2017; 40(6):255-260. PubMed ID: 29059133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson's disease.
    Herz DM; Haagensen BN; Nielsen SH; Madsen KH; Løkkegaard A; Siebner HR
    Mov Disord; 2016 Apr; 31(4):521-9. PubMed ID: 26954295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection and assessment of the severity of levodopa-induced dyskinesia in patients with Parkinson's disease by neural networks.
    Keijsers NL; Horstink MW; van Hilten JJ; Hoff JI; Gielen CC
    Mov Disord; 2000 Nov; 15(6):1104-11. PubMed ID: 11104192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
    Nutt JG; Carter JH; Carlson NE
    Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
    Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
    Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease.
    Antonini A; Nitu B
    J Neural Transm (Vienna); 2018 Aug; 125(8):1131-1135. PubMed ID: 30006821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk thresholds of levodopa dose for dyskinesia in Chinese patients with Parkinson's disease: a pilot study.
    Liu G; Chen H; Su D; Wang D; Zhang M; Wang X; Wang Z; Yang Y; Jiang Y; Ma H; Feng T
    Neurol Sci; 2020 Jan; 41(1):111-118. PubMed ID: 31446577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subthalamic nucleus deep brain stimulation improves dyskinesias in Parkinson's disease beyond levodopa reduction.
    Mossner JM; Patil PG; Chou KL
    J Neural Transm (Vienna); 2019 Nov; 126(11):1479-1483. PubMed ID: 31494731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.